Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NIS793 + Sabatolimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NIS793 | nisevokitug | TGFB (Pan) Antibody 5 | NIS793 is a monoclonal anti-transforming growth factor beta (TGF-beta) antibody that blocks TGF-beta signaling, leading to tumor growth inhibition (PMID: 31692434). | |
Sabatolimab | MBG453|MBG-453|MBG 453 | Immune Checkpoint Inhibitor 149 TIM-3 Antibody 9 | Sabatolimab (MBG453) is monoclonal antibody that targets T-cell immunoglobulin and mucin domain-3 protein (TIM-3, HAVCR2), potentially resulting in enhanced anti-tumor immune response (PMID: 29544515, PMID: 31847708). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04810611 | Phase I | NIS793 Sabatolimab Canakinumab + Sabatolimab NIS793 + Sabatolimab Canakinumab | Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS | Terminated | USA | ITA | ISR | ESP | AUS | 2 |